KUR 115

Drug Profile

KUR 115

Alternative Names: KUR115

Latest Information Update: 25 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptide hormones; Serine endopeptidases
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bone disorders

Most Recent Events

  • 15 Oct 2015 Pharmacodynamics and adverse events data from a preclinical trial in Spinal fusion released by Kuros Biosurgery
  • 08 Sep 2015 Phase-I clinical trials in Spinal fusion in USA (unspecified route) before September 2015
  • 08 Sep 2015 Kuros plans a phase II trial for Bone disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top